Saturday, December 21, 2024

LIGHT-ACTIVATED LIPOSOMES FOR GLAUCOMA

 


Biomedical researchers at Binghamton University in the USA, have developed a mechanism for drug-carrying liposomes that can be activated in the eye using near-infrared light.

The remotely triggered on-demand liposomal delivery system has been studied to treat glaucomatous neurodegeneration in mice.

The researchers overcame some difficulties in their drug delivery mechanism. “The first problem we found is that most pharmacological compounds are hydrophobic, which means they have low water solubility,” Wang said. “The second problem is using a thermal effect to trigger the release — how do we do that without affecting a patient’s comfort or having side effects?”

The scientists utilized the localized surface plasmon resonance (LSPR) effect of gold nanorods (AuNRs) under near-infrared (NIR) light (808 nm) to control the release of cyclodextrin-encapsulated melatonin from thermally responsive liposomal nanocarriers in the vitreous humor.

The liposomes—which are small, spherical, artificial vesicles that can deliver drugs and other molecules to specific sites in the body—have the gold nanorods embedded on their fatty surface. The gold heats up under a specific near-infrared wavelength and breaks down the membrane to release the needed medication, which is mixed with cyclodextrin to aid its absorption into the eye.


Due to the transparency of the eye's cornea, NIR light can penetrate deep tissues, enabling on-demand drug delivery to the retina.

By enhancing the drug's solubility and stability through cyclodextrin encapsulation, this remotely activated melatonin/HPβCD AuNRs liposomes delivery system can decrease intraocular pressure (IOP) elevation by (24 ± 7)%, enhance the survival rate of RGCs by (77 ± 6)%, and decrease glial fibrillary acidic protein (GFAP) activation by (75 ± 6)% at depth in an acute experimental glaucoma model.

This NIR-triggered drug delivery system presents the potential of a promising minimally photo-triggered therapeutic option for glaucoma treatment.

The scientists call it a minimally-invasive procedure, as they claim that the patient will need only a one-time injection that will be sufficient to lower the IOP.

REFERENCE:
Matuwana D, Hong E, Huang S, Xu X, Jang G, Xiao R, Rao S, Wang Q. Near-infrared activated liposomes for neuroprotection in glaucoma. J Mater Chem B. 2024 Oct 30;12(42):10902-10914. doi: 10.1039/d4tb00745j. PMID: 39355895.



No comments:

Post a Comment

LIGHT-ACTIVATED LIPOSOMES FOR GLAUCOMA

  Biomedical researchers at Binghamton University in the USA, have developed a mechanism for drug-carrying liposomes that can be activated i...